Provided that a number of potential adverse side-effects could bemanaged, high-affinity PPARβ/δ synthetic ligands would clearly be useful drugs ofthe future to effectively target some of the most important abnormalitiesassociated with the metabolic syndrome such as insulin resistance,hyperglycemia, and dyslipidemia [46]. Here, PPARD is linked to metabolic syndrome.